Shifeng Yang1, Zhengbo Song2, Guoping Cheng1. 1. Department of Pathology, Zhejiang Cancer Hospital, Hangzhou 310022, China. 2. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Abstract
BACKGROUND: Young patients are rarely diagnosed with non-small cell lung cancer (NSCLC), and little is known about its predisposing genomic alterations and survival. METHODS: This retrospective study was conducted to evaluate the genomic alterations, treatment and prognosis of young patients under 40 years old from a cohort of 640 lung adenocarcinoma and squamous carcinoma cases from Zhejiang Cancer Hospital. All patients were examined for EGFR, KRAS, NRAS, PIK3CA, BRAF and HER2 mutations and ALK, ROS1 and RET fusion genes. RESULTS: In total, 54 patients were aged under 40 years. The frequencies of genomic alterations in younger (≤40 years) and older (>40 years) patients were 68.5% and 54.8%, respectively (P=0.05). Younger patients harbored a higher frequency of fusion genes (22.2% vs. 4.1%, P<0.001) but not gene mutations (46.3% vs. 45.6%, P=0.92). There was a general trend toward shorter recurrence-free survival (RFS) (35.2 vs. 43.8 months, P=0.050), while no overall survival (OS) difference existed between younger and older patients (50.2 vs. 51.4 months, P=0.112). CONCLUSIONS: Younger patients with NSCLC had a higher frequency of gene fusions than older patients and had a trend of worse OS.
BACKGROUND: Young patients are rarely diagnosed with non-small cell lung cancer (NSCLC), and little is known about its predisposing genomic alterations and survival. METHODS: This retrospective study was conducted to evaluate the genomic alterations, treatment and prognosis of young patients under 40 years old from a cohort of 640 lung adenocarcinoma and squamous carcinoma cases from Zhejiang Cancer Hospital. All patients were examined for EGFR, KRAS, NRAS, PIK3CA, BRAF and HER2 mutations and ALK, ROS1 and RET fusion genes. RESULTS: In total, 54 patients were aged under 40 years. The frequencies of genomic alterations in younger (≤40 years) and older (>40 years) patients were 68.5% and 54.8%, respectively (P=0.05). Younger patients harbored a higher frequency of fusion genes (22.2% vs. 4.1%, P<0.001) but not gene mutations (46.3% vs. 45.6%, P=0.92). There was a general trend toward shorter recurrence-free survival (RFS) (35.2 vs. 43.8 months, P=0.050), while no overall survival (OS) difference existed between younger and older patients (50.2 vs. 51.4 months, P=0.112). CONCLUSIONS: Younger patients with NSCLC had a higher frequency of gene fusions than older patients and had a trend of worse OS.
Entities:
Keywords:
Genomic alterations; age; non-small cell lung cancer (NSCLC); survival
Authors: R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger Journal: N Engl J Med Date: 2000-01-13 Impact factor: 91.245
Authors: G Cancello; P Maisonneuve; N Rotmensz; G Viale; M G Mastropasqua; G Pruneri; P Veronesi; R Torrisi; E Montagna; A Luini; M Intra; O Gentilini; R Ghisini; A Goldhirsch; M Colleoni Journal: Ann Oncol Date: 2010-03-23 Impact factor: 32.976
Authors: D Mauri; G Pentheroudakis; D Bafaloukos; D Pectasides; E Samantas; E Efstathiou; H P Kalofonos; K Syrigos; G Klouvas; P Papakostas; P Kosmidis; G Fountzilas; N Pavlidis Journal: Anticancer Res Date: 2006 Jul-Aug Impact factor: 2.480
Authors: Hanna Fredholm; Sonja Eaker; Jan Frisell; Lars Holmberg; Irma Fredriksson; Henrik Lindman Journal: PLoS One Date: 2009-11-11 Impact factor: 3.240